PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR -ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1. HEPATITIS C: WEEK 4 INTERIM RESULTS (vol 48, pg 4, 2008)

被引：0
|
作者：
Forns, X. [1 ]
Marcellin, P. [2 ]
Goeser, T. [3 ]
Ferenci, P. [4 ]
Nevens, F. [5 ]
Carosi, G. [6 ]
Drenth, J. P. [7 ]
De Backer, K. [8 ]
van Heeswijk, R. [8 ]
Vangeneugden, T. J. [8 ]
Picchio, G. [9 ]
Beumont-Mauviel, M. [8 ]
机构：
[1] Univ Barcelona, Liver Unit, Barcelona, Spain
[2] Hop Beaujon, Clichy, France
[3] Klinikum Univ Koln, Cologne, Germany
[4] Med Univ Vienna, Dept Internal Med 3, Vienna, Austria
[5] Univ Hosp Gasthuisberg, Dept Hepatol, B-3000 Louvain, Belgium
[6] Univ Brescia, Clin Infect & Trop Dis, Brescia, Italy
[7] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[8] Tibotec BVBA, Mechelen, Belgium
[9] Tibotec Inc, Yardley, PA USA
来源：
HEPATOLOGY | 2008年 / 48卷 / 06期
关键词：
D O I：
10.1002/hep.22702
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：2093 / 2093
页数：1
相关论文
共 50 条
  • [21] Treatment week 12 results of weight-based taribavirin versus weight-based ribavirin, both with peginterferon alfa-2B, in naive chronic hepatitis C, genotype 1 patients
    Poordad, F.
    Lawitz, E.
    Chun, E.
    Hammond, J.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S373 - S373
  • [22] BOCEPREVIR (BOC) COMBINED WITH PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) FOR TREATMENT-NAiVE PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE (G) 1: SPRINT-2 FINAL RESULTS
    Poordad, Fred
    McCone, Jonathan
    Bacon, Bruce R.
    Bruno, Savino
    Manns, Michael P.
    Sulkowski, Mark S.
    Jacobson, Ira M.
    Reddy, K. Rajender
    Boparai, Navdeep
    Sniukiene, Vilma
    Brass, Clifford A.
    Albrecht, Janice K.
    Bronowicki, Jean-Pierre
    HEPATOLOGY, 2010, 52 (04) : 402A - 403A
  • [23] A pilot study of add-on oral hypoglycemic agents in treatment-naive genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin
    Hsu, Ching-Sheng
    Hsu, Shih-Jer
    Lin, Hans Hsienhong
    Tseng, Tai-Chung
    Wang, Chia-Chi
    Chen, Ding-Shinn
    Kao, Jia-Horng
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2014, 113 (10) : 716 - 721
  • [24] TREATMENT WEEK 24 RESULTS OF WEIGHT-BASED TARIBAVIRIN VERSUS WEIGHT-BASED RIBAVIRIN, BOTH WITH PEGINTERFERON ALFA-2B, IN NAiVE CHRONIC HEPATITIS C, GENOTYPE 1 PATIENTS
    Lawitz, Eric
    Muir, Andrew J.
    Poordod, Fred
    Chun, Eric
    Hammond, Janet
    HEPATOLOGY, 2008, 48 (04) : 433A - 434A
  • [25] Comparable antiviral response rates with albumin interferon alfa-2b dosed at Q2W or Q4W intervals in naive subjects with genotype 2 or 3 chronic hepatitis C
    Bain, V. G.
    Marotta, P.
    Kaita, K.
    Yoshida, E.
    Swain, M.
    Bailey, R.
    Neumann, A.
    Cronin, P.
    McHutchison, J.
    Pulkstenis, E.
    Subramanian, M.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S7 - S7
  • [26] A RANDOMIZED TRIAL OF 24-VERSUS 48-WEEK PEGINTERFERON ALFA-2A PLUS RIBAVIRIN FOR TREATMENT-NAiVE TAIWANESE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION
    Liu, Chen-Hua
    Liu, Chun-Jen
    Lin, Chih-Lin
    Liang, Cheng-Chao
    Hsu, Shih-Jer
    Yang, Sheng-Shun
    Hsu, Ching-Sheng
    Tseng, Tai-Chung
    Wang, Chia-Chi
    Lai, Ming-Yang
    Chen, Jun-Herng
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    HEPATOLOGY, 2008, 48 (04) : 320A - 320A
  • [27] Assessment of both virological response at week 4 and at week 12 optimizes prediction of treatment outcome in patients with chronic hepatitis C treated with peginterferon alfa-2b plus ribavirin
    Martinot-Peignoux, Michelle
    Maylin, Sarah
    Ripault, Marie Pierre
    Moucari, Rami
    Boyer, Nathalie
    Giuily, Nathalie
    Castelnau, Corinne
    Marcellin, Patrick
    HEPATOLOGY, 2007, 46 (04) : 374A - 375A
  • [28] ADHERENCE TO ASSIGNED DOSING REGIMEN AND SUSTAINED VIROLOGIC RESPONSE AMONG HEPATITIS C GENOTYPE 1 TREATMENT-NAIVE AND PEG/RIBAVIRIN TREATMENT-FAILURES TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN
    Gordon, S. C.
    Lawitz, E. J.
    Bacon, B. R.
    Sulkowski, M. S.
    Yoshida, E. M.
    Davis, M.
    Boparai, N.
    Sniukiene, V.
    Burroughs, M.
    Brass, C. A.
    Albrecht, J. K.
    Reddy, K. R.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S173 - S174
  • [29] PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)
    Reddy, K. R.
    Bruno, S.
    Rossaro, L.
    Ravendhran, N.
    Pauly, M. P.
    Boparai, N.
    Sniukiene, V.
    Brass, C. A.
    Albrecht, J. K.
    Poordad, F.
    Jacobson, I. M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S190 - S190
  • [30] Adherence to Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C Genotype 1 Treatment-NaiVE and PEG/Ribavirin Treatment-Failures Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin
    Gordon, Stuart C.
    Lawitz, Eric J.
    Bacon, Bruce R.
    Sulkowski, Mark
    Yoshida, Eric M.
    Davis, Mitchell N.
    Boparai, Navdeep
    Sniukiene, Vilma
    Burroughs, Margaret
    Brass, Clifford A.
    Albrecht, Janice K.
    Reddy, Rajender
    GASTROENTEROLOGY, 2011, 140 (05) : S944 - S944
12345